Esophageal Adenocarcinoma
Therapeutic response
Precision oncology relationships for therapeutic response involving this cancer type.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (1) | PD-L1 (CPS) >= 10 | Esophageal Adenocarcinoma | Pembrolizumab | |
| EMA (1) | PD-L1 (CPS) >= 10 | Esophageal Adenocarcinoma | Cisplatin, Fluorouracil, Pembrolizumab | |
| EMA (1) | PD-L1 (CPS) >= 10 | Esophageal Adenocarcinoma | Carboplatin, Fluorouracil, Pembrolizumab | |
| EMA (1) | HER2-negative, PD-L1 (CPS) >= 5 | Esophageal Adenocarcinoma | Fluorouracil, Nivolumab, Oxaliplatin | |
| EMA (1) | HER2-negative, PD-L1 (CPS) >= 5 | Esophageal Adenocarcinoma | Nivolumab, Oxaliplatin |